Total Payments
$67,006
2024 Payments
$25,447
Companies
72
Transactions
462
Medicare Patients
6,891
Medicare Billing
$3.0M
Payment Breakdown by Category
Other$28,553 (42.6%)
Consulting$28,429 (42.4%)
Food & Beverage$9,546 (14.2%)
Education$296.69 (0.4%)
Travel$182.02 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $28,429 | 20 | 42.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $26,828 | 7 | 40.0% |
| Food and Beverage | $9,546 | 421 | 14.2% |
| Compensation for serving as faculty or as a speaker for a medical education program | $1,725 | 1 | 2.6% |
| Education | $296.69 | 10 | 0.4% |
| Travel and Lodging | $182.02 | 3 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $27,736 | 24 | $0 (2024) |
| Daiichi Sankyo Inc. | $8,929 | 22 | $0 (2024) |
| Astellas Pharma US Inc | $6,658 | 10 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $3,967 | 49 | $0 (2024) |
| GENZYME CORPORATION | $3,332 | 13 | $0 (2024) |
| TG THERAPEUTICS, INC. | $2,025 | 1 | $0 (2021) |
| CTI BioPharma Corp. | $1,867 | 3 | $0 (2023) |
| Karyopharm Therapeutics Inc. | $1,623 | 5 | $0 (2023) |
| Janssen Scientific Affairs, LLC | $1,555 | 2 | $0 (2022) |
| Seagen Inc. | $1,262 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $25,447 | 141 | GlaxoSmithKline, LLC. ($21,363) |
| 2023 | $15,398 | 108 | GlaxoSmithKline, LLC. ($6,358) |
| 2022 | $10,388 | 63 | Daiichi Sankyo Inc. ($4,133) |
| 2021 | $13,015 | 25 | Astellas Pharma US Inc ($4,576) |
| 2020 | $338.29 | 13 | Astellas Pharma US Inc ($115.43) |
| 2019 | $1,085 | 39 | Novartis Pharmaceuticals Corporation ($274.79) |
| 2018 | $443.65 | 25 | Alexion Pharmaceuticals, Inc. ($121.84) |
| 2017 | $891.95 | 48 | Alexion Pharmaceuticals, Inc. ($486.32) |
All Payment Transactions
462 individual payment records from CMS Open Payments — Page 1 of 19
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $26.21 | General |
| Category: ONCOLOGY | ||||||
| 12/18/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $14.68 | General |
| 12/17/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $3.14 | General |
| Category: Immunology | ||||||
| 12/12/2024 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug) | Food and Beverage | In-kind items and services | $20.76 | General |
| Category: Oncology | ||||||
| 12/10/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $15.15 | General |
| Category: Oncology | ||||||
| 12/09/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $22.85 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $22.32 | General |
| Category: Hematology/Oncology | ||||||
| 12/02/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $14.34 | General |
| Category: ONCOLOGY | ||||||
| 11/23/2024 | Octapharma USA, Inc. | OCTAGAM IMMUNE GLOBULIN (HUMAN) (Biological) | Food and Beverage | In-kind items and services | $22.93 | General |
| Category: IMMUNOLOGY | ||||||
| 11/21/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $22.46 | General |
| Category: Genetically Defined Disease | ||||||
| 11/18/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $21.84 | General |
| Category: Hematology | ||||||
| 11/18/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $19.45 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/15/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $16.43 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 11/14/2024 | Myriad Genetic Laboratories, Inc. | MYRISK (Device) | Food and Beverage | In-kind items and services | $19.25 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $15.60 | General |
| Category: Immunology | ||||||
| 11/13/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $15.03 | General |
| Category: CELLT | ||||||
| 11/11/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $5.17 | General |
| Category: Oncology | ||||||
| 11/11/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $0.61 | General |
| Category: Oncology | ||||||
| 11/05/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $19.60 | General |
| Category: Oncology | ||||||
| 10/31/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $13.46 | General |
| Category: ONCOLOGY | ||||||
| 10/30/2024 | PFIZER INC. | IBRANCE (Drug) | Food and Beverage | In-kind items and services | $9.00 | General |
| Category: ONCOLOGY | ||||||
| 10/28/2024 | BeiGene USA, Inc. | TEVIMBRA (Drug) | Food and Beverage | In-kind items and services | $20.91 | General |
| Category: Oncology | ||||||
| 10/25/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $16.74 | General |
| 10/23/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $8.90 | General |
| Category: Immunology | ||||||
| 10/22/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $124.98 | General |
| Category: Genetically Defined Disease | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 46 | 1,737 | 88,664 | $2.9M | $1.1M |
| 2022 | 47 | 1,680 | 68,798 | $1.6M | $611,961 |
| 2021 | 44 | 1,724 | 52,980 | $1.3M | $516,813 |
| 2020 | 48 | 1,750 | 72,592 | $2.1M | $798,136 |
Total Patients
6,891
Total Services
283,034
Medicare Billing
$3.0M
Procedure Codes
185
All Medicare Procedures & Services
185 procedure records from CMS Medicare Utilization — Page 1 of 8
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 27 | 12,000 | $1.2M | $509,769 | 43.0% |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 2023 | 15 | 3,090 | $266,605 | $111,008 | 41.6% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 37 | 4,500 | $167,220 | $82,775 | 49.5% |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | Office | 2023 | 15 | 2,690 | $397,205 | $57,904 | 14.6% |
| A9595 | Piflufolastat f-18, diagnostic, 1 millicurie | Office | 2023 | 13 | 117 | $140,400 | $49,776 | 35.5% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 49 | 49 | $107,618 | $37,611 | 34.9% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 111 | 329 | $132,587 | $30,974 | 23.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 76 | 240 | $67,546 | $30,546 | 45.2% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 13 | 11,650 | $87,958 | $27,608 | 31.4% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 38 | 38 | $30,400 | $22,269 | 73.3% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 19 | 20,250 | $42,930 | $17,731 | 41.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 153 | 219 | $30,682 | $12,407 | 40.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 72 | 135 | $27,964 | $11,925 | 42.6% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 17 | 88 | $40,201 | $11,720 | 29.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 36 | 93 | $14,508 | $8,402 | 57.9% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 86 | 182 | $32,942 | $8,206 | 24.9% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 27 | 27 | $13,068 | $3,947 | 30.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 23 | 23 | $9,247 | $3,443 | 37.2% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 90 | 276 | $17,664 | $3,142 | 17.8% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 59 | 136 | $13,600 | $2,878 | 21.2% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 32 | 60 | $11,880 | $2,796 | 23.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 31 | 40 | $4,400 | $2,436 | 55.4% |
| 71260 | Ct scan of chest with contrast | Office | 2023 | 29 | 30 | $14,100 | $2,360 | 16.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 17 | 18 | $7,179 | $2,248 | 31.3% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 50 | 55 | $4,577 | $2,133 | 46.6% |
About Dr. Mark Marinella, MD
Dr. Mark Marinella, MD is a Hematology & Oncology healthcare provider based in Kettering, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/18/2005. The National Provider Identifier (NPI) number assigned to this provider is 1801888482.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Marinella, MD has received a total of $67,006 in payments from pharmaceutical and medical device companies, with $25,447 received in 2024. These payments were reported across 462 transactions from 72 companies. The most common payment nature is "Consulting Fee" ($28,429).
As a Medicare-enrolled provider, Marinella has provided services to 6,891 Medicare beneficiaries, totaling 283,034 services with total Medicare billing of $3.0M. Data is available for 4 years (2020–2023), covering 185 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Medical Oncology
- Location Kettering, OH
- Active Since 08/18/2005
- Last Updated 05/14/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1801888482
Products in Payments
- OJJAARA (Drug) $27,693
- XTANDI (Drug) $4,672
- ENHERTU (Drug) $4,133
- Enhertu (Drug) $3,537
- SARCLISA (Biological) $2,625
- UKONIQ (Drug) $2,025
- Vonjo (Drug) $1,867
- IMBRUVICA (Drug) $1,804
- PROMACTA (Drug) $1,682
- XPOVIO (Drug) $1,623
- SOLIRIS (Drug) $608.16
- JEVTANA (Drug) $600.01
- IMFINZI (Biological) $537.49
- Tepmetko (Drug) $500.00
- KEYTRUDA (Biological) $494.21
- OPDIVO (Biological) $439.42
- KISQALI (Drug) $291.43
- Yescarta (Drug) $219.36
- JAKAFI (Drug) $217.25
- Trodelvy (Drug) $207.82
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Kettering
Alejandro Calvo, Md, MD
Hematology & Oncology — Payments: $633,172
Hematology & Oncology $633,172
Satheesh Kathula, Md, MD
Hematology & Oncology — Payments: $232,557
Hematology & Oncology $232,557
Dr. Tarek Sabagh, Md, MD
Hematology & Oncology — Payments: $189,729
Hematology & Oncology $189,729
Manish Sheth, Md, MD
Hematology & Oncology — Payments: $31,320
Hematology & Oncology $31,320
Dr. Burhan Yanes, Md, MD
Hematology & Oncology — Payments: $17,917
Hematology & Oncology $17,917
Brandon Cutler, Do, DO
Hematology & Oncology — Payments: $2,168
Hematology & Oncology $2,168